Member Info for DRB83

Johnk, it happened last Friday and Monday was a 15% blue day. This time it's the CEO. Looking forward to Monday. The SP needed a spark to push it over the £2.50 line. I suspect it just got it. GLA

All set to blow the socks off £2.50 next week then. Monday's are now my new Fridays. GLA

Nice one DA. Looks like it only went through today at 15:50

Not sure exactly what the op margins will be on the labs but usually with testing most of the costs are spent at the beginning so the more volumes we have the more the margins should increase. Looking for upward of 50% op margin. Not bad on 60k tests per month. £5m monthly op margin by end of 2023. Let's see.

Vas, I believe it's 20k capacity per lab.

Time will tell. Not long to wait

Unlikely imo HarChris. DA would have had a good idea of what Jan looked like when he gave is guidance end of Jan.

Muggins, that is far from a disposal of shares. Both GB and CG sacrificed £450k because they felt it was the right thing to do for the company and shareholders. As if they would gladly sell shares for 8p when they are worth 27p at the time. They would have clearly converted to shares and kept them if they wanted to dilute shareholders. They didn't have to but they chose cash. Now your using it as a negative. Poor form.

Some of it went here:

After extensive due diligence undertaken by Enterprise Ireland, we have secured their financial and global network support to accelerate mass production design to meet the demand of not just the industrial scale COVID19 pandemic response equipment but to reduce the size and lower the cost of early warning disease monitoring equipment as part of the Digital Health Revolution.

Getting to mass produced instruments of different sizes and costs is a key priority of our business to fulfil this worldwide need and we have invested heavily and will continue to invest to create a new generation of instruments that the market demands.

Some of it went here:

Additional investment from the recent £10m placing has facilitated the completion of the laboratories upgrade in York, UK, to provide capacity for processing up to 20,000 Skin Trust Club home test kits per month, for the UK market, subject only to delivery of gene sequencing machines, expected to arrive in early September. Details on the launch of the Skin Trust Club Android app and marketing campaign to commence in September engaging the skills of a, soon to be announced, top global media agency are highlighted in today's Annual General Meeting ("AGM") presentation.



Demand received from consumers and B2B partners, such as beauticians and dermatologists, has resulted in completion of more than 5,000 tests which was the limit of capacity up to the end of June. Further demand has arisen from Labskin skincare corporate clients requesting to include home test kits before and after product and ingredient tests for each human test subject in contract clinical trials, which exceeds current service capacity and is expected to increase outside of any consumer related marketing campaign.



As well as processing capacity for 20,000 units in the UK by Q4 2021, preparations are underway for the same volume for the US market, expected to launch in H1 2022. In addition, Labskin is completing development of ethnic skin model testing which will enable a similar volume of 20,000 units per month in China targeted for launch in H2 2022 in 5 major cities (Shanghai, Beijing, Tianjin, Shenzhen and Guangzhou) that have a combined population of c80m.

Some will have gone on working capital.

We don't know how much is left but it won't be zero.

£50m is revenue, not cash. Cash conversion is 32% ish. Better to exclude a favourable resolution so in my opinion cash is more likely to be £115-120m. That's the conservative approach. The target however should be closer to £130m.

No way to be sure it's a buy?

LT, yes was just using the standard type to put perspective on the volume.

At least 20% of the orders were for CTM for the Middle East. We don't know the split of the orders but as it's only Q1 orders I fully expect them to be delivered in FY22.

The 5 year lease option will help boost demand significantly imo. It's a smaller pill to swallow than $40k upfront and will be a very attractive option for many businesses.

£5m is what approx 200 units. Come July, that will be our monthly production capacity. Shouldn't be too difficult to deliver those and many more this FY.

The main thing for me is that the orders are there. The demand is there. Everything else I assume will look after itself.

Heuy, extract from Google below:

Essentially the non-executive director's (NED) role is to provide a creative contribution to the board by providing independent oversight and constructive challenge to the executive directors.

The 1992 Cadbury Report initiated a debate about the main functions and responsibilities of non-executive directors. Today, it is widely accepted that non-executive directors have an important contribution to make to the proper running of companies and, therefore, more widely to the economy at large. As the Cadbury Report said, they “should bring an independent judgement to bear on issues of strategy, performance and resources including key appointments and standards of conduct”.

In order for a NED to do their job properly they will clearly need access to sensitive inside information. Therefore, I strongly suspect they will be treated the same as executive directors when it comes to buying and selling shares.

I'm saying it is possible. Assuming they are following the reporting rules. If they are not following the reporting rules then yes your scenario is also possible. I'm still hopeful of a TR1 today but not holding my breath. It will come when it comes but there build up just seems so slow for it to be a TO attempt. They're giving ncyt ample time to decide their defence options.

French volume was a lot higher that day HarChris. It is possible that they filled their boots Monday 7th. I believe Bio would be buying on the EuroNext. Who knows but I am very surprised yet again to not have had another holdings RNS from them by now.

Bio got to 5.54% on the 7th. We should have now heard of their holdings upto Monday 14th if they had past 6%. That means, if Bio are following the reporting rules then they haven't bought more than 300k shared between 8th and 14th March. In that time the SP has ranged from 134 to 214. That would have been prime time for them to be buying, but by the looks of it, they choose to stop. That is soooooooo slooooooooow and surely can't be categorised as a hostile TO attempt. Not even sure it qualifies as a TO attempt. Would love to know their intentions. Very frustrating.

It took them weeks to go from 4% to 5.54% which I put down to the uncertainties of the Russia Ukraine war. The market has settled since then so what is their reason now for halting. I'm very curious given they are a competitor and not a II.

The guy running the numbers, the guy who goes to all the important meetings has just basically told everyone, now is a great time to buy. That'll do for me.

That would be even better yes